Grant Harrison Gershner, MD | |
7703 Floyd Curl Dr, San Antonio, TX 78229-3901 | |
(210) 567-7000 | |
Not Available |
Full Name | Grant Harrison Gershner |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 7703 Floyd Curl Dr, San Antonio, Texas |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013537398 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2086S0120X | Surgery - Pediatric Surgery | BP10070471 (Texas) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | BP10070471 (Texas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Grant Harrison Gershner, MD 7703 Floyd Curl Dr # 7742, San Antonio, TX 78229-3900 Ph: (210) 567-5711 | Grant Harrison Gershner, MD 7703 Floyd Curl Dr, San Antonio, TX 78229-3901 Ph: (210) 567-7000 |
News Archive
In a national online survey conducted by the American Society of Registered Nurses, 41% of the 781 Registered Nurses surveyed on April 28 reported that generic drugs are less effective than their equivalent brand-name counterparts.
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the third dose of the Pfizer/BioNTech BNT162B2 vaccine against the Delta variant of SARS-CoV-2.
Immune suppressor cells called MDSCs (myeloid-derived suppressor cells) may be important in developing treatments for advanced prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center.
Endo International plc today announced it has entered into a definitive agreement under which Endo will acquire Grupo Farmaceutico Somar, a leading privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for cash consideration. Endo expects the transaction to be immediately accretive to adjusted earnings per share.
› Verified 1 days ago